PubMed Health⌕ Search

Biomedical subjects

Kartik J Desai

Publications and source records attributed to Kartik J Desai.

2 recordsLinked to original sources

Ischemia induced focal adhesion kinase cleavage in rat lung.

Focal adhesion kinase (FAK), a 125 kDa protein, is located at the focal adhesion sites that stabilize endothelial cells on the matrix. Ischemic stimuli cause FAK cleavage and FAK depletion from focal adhesion sites. To test this hypothesis under ischemic conditions, we established an isolated rat lung that we ventilated at 40 inflations/min at inspiratory and expiratory pressures of 10 and 3 cm H2O, respectively. After 5 min of blood perfusion at pulmonary arterial and left atrial pressures of 13 and 3 cm H2O respectively, we either stopped (ischemic group, n=10) or continued (perfused group, n=10) perfusion for 2 hr. We then recovered endothelial cells from each lung, using our previously reported magnetic cell separation method. The endothelial lysates were separated into cytosol and membrane fractions, then immunoprecipitated and blotted with anti-FAK, and anti-phospho-FAK antibody. In ischemic as compared to perfused lungs, immunoblotting with anti-FAK antibody revealed a greater prominence of bands at 125 kDa as well as at cleavage products 80, 70 and 44 kDa in the cytosol fraction. Immuno-blotting with anti-phosphotyrosine antibody revealed decreased enhancement of bands at 80, 70 and 44 kDa, also at 125 kDa in the cytosol fraction. We propose that during lung ischemia, FAK is dephosphorylated, cleaved and translocated to the cytosol. This first evidence of the involvement of FAK in lung ischemia suggests that destabilization of focal adhesions may underlie endothelial barrier deterioration, contributing to increased vascular permeability in ischemic lung injury.

Acetylation↗

Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation.

OBJECTIVES: The study was done to investigate the relationship between clinical restenosis and the relative angiographic location of the recurrent restenotic lesion, after treatment of in-stent restenosis with vascular brachytherapy in the Washington Radiation for In-Stent Restenosis Trial (WRIST). BACKGROUND: Intracoronary radiation therapy reduces recurrence of in-stent restenosis. We investigated the above objective in patients enrolled in WRIST. METHODS: The WRIST study randomized 130 patients to double-blinded therapy with gamma irradiation (iridium-192 [(192)Ir]) versus placebo after interventional treatment of diffuse in-stent restenosis. After the intervention and at follow-up, three vessel segments were individually analyzed with quantitative coronary angiography: 1) the "stent," 2) the "radiation ribbon," and 3) the "ribbon+margin" segment (including 5 mm on either end of the injured or radiation-ribbon segment). Receiver operator curves (ROC) were used to assess the value of the follow-up percent diameter stenosis (DS) for each of the three analyzed segments in predicting target vessel revascularization (TVR). RESULTS: (192)Ir reduced recurrent restenosis (23.7% vs. 60.7%, p < 0.001) and the length of recurrent restenosis (8.99 +/- 4.34 mm vs. 17.54 +/- 10.48 mm, p < 0.001) at follow-up compared to placebo. Isolated stent edge (3.4%) and ribbon edge (1.7%) restenoses were infrequent in both groups. The best angiographic surrogate of TVR was the 50% follow-up DS obtained from the ribbon+margin analysis (ROC area 0.806). CONCLUSIONS: In WRIST, not only was (192)Ir therapy effective in reducing restenosis, but it also reduced the lesion length of treatment failures by 50%, and it was not associated with edge proliferation. The restenosis rate obtained from the vessel segment inclusive of the dose fall-off zones was the best correlate of TVR and should become a standard analysis site in all vascular brachytherapy trials.

Brachytherapy↗